Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991216 | 1.00 | GBA1 (0.33) | GBA1L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL8324468 | 1.00 | GBA1 (0.33) | GBA1L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL9387801 | 0.85 | SLC6A2 (0.32) | HTR1ASIGMAR1CYP19A1 | |
| SCHEMBL8449850 | 0.83 | DGAT1 (0.45) | MAPT | |
| SCHEMBL8319230 | 0.79 | HTT (0.38) | L3MBTL1NPC1MAPTRAB9AHTT | |
| SCHEMBL6015851 | 0.79 | HTT (0.38) | L3MBTL1NPC1MAPTRAB9AHTT | |
| SCHEMBL9385274 | 0.79 | CYP26A1 (0.39) | MAPTHTR1ASIGMAR1CYP19A1 | |
| SCHEMBL9385160 | 0.77 | L3MBTL1 (0.34) | GBA1L3MBTL1NPC1MAPTRAB9A | |
| SCHEMBL1999145 | 0.77 | BUB1 (0.32) | L3MBTL1HTTATM | |
| SCHEMBL8452787 | 0.75 | TBXAS1 (0.36) | L3MBTL1NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0574783-B1 | Asymmetric hydrogenation | HOFFMANN LA ROCHE (CH) | 1999-10-06 | — | — | EP | claimed |
| US-5374727-A | Using rhodium-diphosphine complex as hydrogenation catalyst | HOFFMANN-LA ROCHE INC. (US) | 1994-12-20 | — | — | US | claimed |
| EP-0574783-A2 | Asymmetric hydrogenation | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-22 | — | — | EP | claimed |
| EP-0574783-B1 | Asymmetric hydrogenation | HOFFMANN LA ROCHE (CH) | 1999-10-06 | — | — | EP | disclosed |
| EP-0624586-B1 | Substituted pyrroles | HOFFMANN LA ROCHE (CH) | 1999-09-01 | — | — | EP | disclosed |
| EP-0540956-B1 | Process for the manufacture of substituted maleimides | HOFFMANN LA ROCHE (CH) | 1997-09-03 | — | — | EP | disclosed |
| US-5399712-A | Protein kinase C inhibitor | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5374727-A | Using rhodium-diphosphine complex as hydrogenation catalyst | HOFFMANN-LA ROCHE INC. (US) | 1994-12-20 | — | — | US | disclosed |
| EP-0624586-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1994-11-17 | — | — | EP | disclosed |
| EP-0574783-A2 | Asymmetric hydrogenation | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-22 | — | — | EP | disclosed |
| EP-0540956-A1 | Process for the manufacture of substituted maleimides | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-12 | — | — | EP | disclosed |